<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897491</url>
  </required_header>
  <id_info>
    <org_study_id>GL 01</org_study_id>
    <nct_id>NCT03897491</nct_id>
  </id_info>
  <brief_title>PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma</brief_title>
  <official_title>Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>photonamic GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>photonamic GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is an open, multicenter, explorative, pilot phase II study in a small number of
      patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy
      (iPDT) with PD L 506 in newly diagnosed supratentorial IDH wild-type glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the incidence of treatment-emergent Adverse Events (safety and tolerability) of iPDT with PD L 506 in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The incidence of treatment-emergent Adverse Events (TEAEs) of CTC grades III, IV and V within two weeks following iPDT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients without tumor progression 12 months after iPDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients who are alive 12 months after iPDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of iPDT until the date of first documented progression, up to 66 months</time_frame>
    <description>Time until first tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of iPDT until the date of death from any cause, up to 66 months</time_frame>
    <description>Time until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGMT promoter methylation status of the patient</measure>
    <time_frame>Baseline</time_frame>
    <description>Analytical results for MGMT promoter methylation status (methylated/unmethylated) in the respective tumor samples of each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune status of the patient</measure>
    <time_frame>Baseline, 2 days, 2 weeks after iPDT and then every 3 months, up to 66 months</time_frame>
    <description>Analytical results for immune parameters (PBMC, CD4+, CD8+) in the respective blood samples of each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of investigator's assessment of patient's physical condition using Karnofsky performance status scale</measure>
    <time_frame>Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months</time_frame>
    <description>To determine patient's physical condition using Karnofsky performance status scale ranging from 0% (worst outcome) to 100% (best outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of investigator's assessment of patient's mental condition using Mini-mental State Examination</measure>
    <time_frame>Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months</time_frame>
    <description>To determine patient's mental condition using Mini-mental State Examination scale ranging from 0 (worst outcome) to 30 (best outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of investigator's assessment of patient's mental condition using National Institutes of Health Stroke Scale</measure>
    <time_frame>Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months</time_frame>
    <description>To determine patient's mental condition using National Institutes of Health Stroke Scale ranging from 0 (best outcome) to 34 (worst outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of investigator's assessment of patient's condition using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Questionnaire (QLQ-C30) together with the Brain module (BM20)</measure>
    <time_frame>Baseline, 2 weeks after iPDT and then every 3 months, up to 66 months</time_frame>
    <description>To determine patient's quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial light transmittance and fluorescence data recorded</measure>
    <time_frame>during iPDT treatment (up to 1 hour)</time_frame>
    <description>To determine whether correlations exist between length of OS/PFS and spectral online-monitoring measurement results (transmission and fluorescence measurements)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial fluorescence data recorded</measure>
    <time_frame>during iPDT treatment (up to 1 hour)</time_frame>
    <description>To determine the rate of patients with fluorescence-negative tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cylindrical diffusor laser probes without kinks, cracks etc. before and after iPDT</measure>
    <time_frame>Day 0 (Treatment day), directly before and after iPDT</time_frame>
    <description>Assessing the safety and performance of the insertion of Cylindrical Diffusor Laser Probes into the brain for iPDT of brain tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of iPDT treatments in which the laser system works properly as planned.</measure>
    <time_frame>Day 0 (Treatment day), directly after iPDT</time_frame>
    <description>Assessing safety and performance of the laser system for iPDT of brain tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of fibers/laser ports which show a maximum deviation in the output power of less than +/-10% to the pre-defined output power of 200 mW/cm diffusor length.</measure>
    <time_frame>Day 0 (Treatment day), directly after iPDT</time_frame>
    <description>Assessing safety and performance of the combination of ML7710i laser system and Cylindrical Diffusor Laser Probes for the iPDT of brain tumors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Interstitial photodynamic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-aminolevulinic acid</intervention_name>
    <description>5-aminolevulinic acid powder for oral solution</description>
    <arm_group_label>Interstitial photodynamic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven, newly diagnosed, supratentorial, unifocal, lobar located IDH wild-type
             glioblastoma according to the criteria of the 2016 WHO classification.

          -  Not safely and/or not completely resectable, lobar located, unifocal, supratentorial
             IDH wild-type glioblastomas with a largest diameter ≤ 40 mm (largest diameter of the
             contrast enhanced tumor, as defined by enhanced T1 MRI sequences) are eligible in case
             of corresponding tumor board re-estimations.

          -  Potentially completely resectable, lobar located, unifocal, supratentorial, IDH
             wild-type glioblastoma with a largest diameter ≤ 40 mm are eligible in case of both
             patient's informed preference in favour of iPDT and corresponding tumor board
             recommendations.

          -  Age 18 - 70 years

          -  Karnofsky Performance status (KPS) of ≥ 70 %

          -  Minimal life expectancy of 3 months.

          -  Patients eligible for radiotherapy plus concomitant and adjuvant chemotherapy with
             temozolomide Adequate haematological function (Absolute neutrophil count (ANC) &gt; 1.5 x
             109/L, Platelet count &gt; 100 x 109/L, Haemoglobin &gt; 10 g/dL (may be transfused to
             maintain or exceed this level)).

          -  International normalized ratio (INR) or PT (secs) and activated partial thromboplastin
             time (aPTT) ≤ 1,5 times of the upper limit of normal in the laboratory where it was
             measured.

          -  Negative pregnancy test in fertile women

          -  For female and male patients of reproductive potential: Willingness to apply highly
             effective contraception (Pearl index &lt;1) during the entire study.

        Such methods include :

          -  combined (estrogen and progestogen containing) hormonal contraception associated with
             inhibition of ovulation:

               -  oral

               -  intravaginal

               -  transdermal

          -  progestogen-only hormonal contraception associated with inhibition of ovulation :

               -  oral

               -  injectable

               -  implantable

          -  intrauterine device (IUD)

          -  intrauterine hormone-releasing system (IUS)

          -  bilateral tubal occlusion

          -  vasectomised partner

          -  sexual abstinence • Written informed consent has been signed prior to or at Visit 1

        Exclusion criteria:

          -  Glioblastomas involving the basal ganglia, the corpus callosum, the primary motor
             cortex, the ventricular system, multifocal tumors, and those involving the brain stem
             and/or the cerebellum.

          -  Glioblastomas exceeding the 40 mm threshold in their largest diameter

          -  Simultaneous use of other potentially phototoxic substances (e.g. tetracyclines,
             sulfonamides, fluoroquinolones, hypericin extracts)

          -  Hypersensitivity against porphyrins

          -  Known diagnosis of porphyria

          -  Acute or chronic hepatic diseases (levels of ASAT, ALAT and/or gamma-GT more than 2.5
             times the upper limit of normal in the laboratory where it was measured)

          -  Manifest renal diseases with renal dysfunction (serum creatinine level &gt; 1.5 times of
             the upper limit of normal in the laboratory where it was measured)

          -  Severe, active co-morbidity:

          -  Unstable angina and/or congestive heart failure within the last 6 months

          -  Transmural myocardial infarction within the last 6 months

          -  History of stroke, cerebral vascular accident, or transient ischemic attack within 6
             months

          -  Serious and inadequately controlled cardiac arrhythmia

          -  Significant vascular disease (e.g. aortic aneurysm)

          -  Evidence of bleeding diathesis or coagulopathy

          -  Acute bacterial or fungal infections

          -  Acute exacerbation of chronic obstructive pulmonary disease

          -  Hepatic insufficiency resulting in clinical jaundice and/or coagulopathy

          -  Acquired immune deficiency syndrome; note, however, that HIV testing is not required
             for study entry.

          -  Inability to undergo MRI (e.g., presence of a pacemaker)

          -  Known intolerance to study medication

          -  Dementia or psychic condition that might interfere with the ability to understand the
             study and thus give a written informed consent

          -  Simultaneous participation in another clinical study or participation in another
             clinical study in the 30 days directly preceding treatment or within 5 plasma
             half-life of the preceding study drug, whatever is longer.

          -  Pregnancy or breastfeeding

          -  In case of both complete absence of intra-operative fluorescence between any of the
             inserted light diffusers and absence of significant surgery-associated bleedings (i.e.
             light transmission is detectable between at least two of the inserted light
             diffusers), the tumor will be classified as 'fluorescence-negative tumor'. iPDT will
             however be performed. Regarding efficacy evaluation, patients with
             fluorescence-negative tumors will be excluded from PP-, but included in the
             ITT-evaluation, and will be evaluated regarding safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Briegel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus Stocker, Dr.</last_name>
    <phone>+49(0)4101/7853-953</phone>
    <email>m.stocker@photonamic.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Friederike Haubenschild</last_name>
    <email>f.haubenschild@photonamic.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Maximilian Ruge, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Niklas Thon, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Walter Stummer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

